Akebia Therapeutics Inc
NASDAQ:AKBA

Watchlist Manager
Akebia Therapeutics Inc Logo
Akebia Therapeutics Inc
NASDAQ:AKBA
Watchlist
Price: 2.04 USD 1.49% Market Closed
Market Cap: 540.9m USD
Have any thoughts about
Akebia Therapeutics Inc?
Write Note

Relative Value

The Relative Value of one AKBA stock under the Base Case scenario is 2.49 USD. Compared to the current market price of 2.04 USD, Akebia Therapeutics Inc is Undervalued by 18%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AKBA Relative Value
Base Case
2.49 USD
Undervaluation 18%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
20
vs Industry
72
Median 3Y
1.6
Median 5Y
1.7
Industry
7.5
Forward
2.2
vs History
vs Industry
Median 3Y
-6
Median 5Y
-1.9
Industry
24.5
Forward
-793.6
vs History
vs Industry
Median 3Y
-9.3
Median 5Y
-4.5
Industry
20.2
vs History
7
vs Industry
Median 3Y
-2.7
Median 5Y
-2.4
Industry
23.4
vs History
17
vs Industry
2
Median 3Y
-6.2
Median 5Y
2
Industry
3.1
vs History
17
vs Industry
63
Median 3Y
1.6
Median 5Y
1.2
Industry
8.2
Forward
2.3
vs History
28
vs Industry
64
Median 3Y
1.9
Median 5Y
2
Industry
9.7
vs History
31
vs Industry
1
Median 3Y
26.6
Median 5Y
0.5
Industry
6
vs History
7
vs Industry
Median 3Y
-3.9
Median 5Y
-1.4
Industry
6.4
Forward
17.7
vs History
vs Industry
Median 3Y
-8.9
Median 5Y
-3
Industry
7.1
vs History
vs Industry
Median 3Y
-8.9
Median 5Y
-3
Industry
5.7
vs History
17
vs Industry
41
Median 3Y
1.7
Median 5Y
1.1
Industry
5.3

Multiples Across Competitors

AKBA Competitors Multiples
Akebia Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Akebia Therapeutics Inc
NASDAQ:AKBA
536.6m USD 2.6 -14.7 24.7 144.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 293 983.5 -162 994.2 -197 927 -195 668.4
US
Abbvie Inc
NYSE:ABBV
387.1B USD 6.6 104 16.9 24.6
US
Amgen Inc
NASDAQ:AMGN
172.3B USD 4.8 24.6 17.8 17.8
US
Gilead Sciences Inc
NASDAQ:GILD
147.6B USD 5.1 18.2 12.2 12.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 054.3 -524.2 -570.8 -555.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104B USD 8.9 28.3 20.6 21.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
69.2B USD 4.9 15.1 14.2 16.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
58B USD 23.6 -181.7 -454 -311.6
AU
CSL Ltd
ASX:CSL
86.7B AUD 3.6 18.8 12.7 15.8
NL
argenx SE
XBRU:ARGX
44.7B EUR 14.3 33.7 58.1 59.7
P/E Multiple
Earnings Growth PEG
US
Akebia Therapeutics Inc
NASDAQ:AKBA
Average P/E: 34.7
Negative Multiple: -14.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 994.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
104
89%
1.2
US
Amgen Inc
NASDAQ:AMGN
24.6
44%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.2
191%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -524.2 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.3
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
8%
1.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -181.7 N/A N/A
AU
CSL Ltd
ASX:CSL
18.8
11%
1.7
NL
argenx SE
XBRU:ARGX
33.7
37%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Akebia Therapeutics Inc
NASDAQ:AKBA
Average EV/EBITDA: 22.2
24.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 927 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.9
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.8
10%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
12.2
7%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -570.8 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.6
16%
1.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.2
9%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -454 N/A N/A
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
NL
argenx SE
XBRU:ARGX
58.1
769%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Akebia Therapeutics Inc
NASDAQ:AKBA
Average EV/EBIT: 39
144.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 668.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.6
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.8
19%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.2
13%
0.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -555.6 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.5
17%
1.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
12%
1.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -311.6 N/A N/A
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
NL
argenx SE
XBRU:ARGX
59.7
N/A N/A